Anidulafungin versus Fluconazole for Invasive Candidiasis
Top Cited Papers
Open Access
- 14 June 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (24), 2472-2482
- https://doi.org/10.1056/nejmoa066906
Abstract
Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis.Keywords
This publication has 25 references indexed in Scilit:
- Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trialThe Lancet, 2005
- Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance StudyClinical Infectious Diseases, 2004
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- Epidemiology and Outcome of Nosocomial and Community-Onset Bloodstream InfectionJournal of Clinical Microbiology, 2003
- Caspofungin versus Amphotericin B for Invasive CandidiasisNew England Journal of Medicine, 2003
- Comparison of Caspofungin and Amphotericin B for Invasive CandidiasisNew England Journal of Medicine, 2002
- Echinocandins — An Advance in the Primary Treatment of Invasive CandidiasisNew England Journal of Medicine, 2002
- Secular Trend of Hospital‐Acquired Candidemia among Intensive Care Unit Patients in the United States during 1989–1999Clinical Infectious Diseases, 2002
- A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without NeutropeniaNew England Journal of Medicine, 1994
- Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990The Journal of Infectious Diseases, 1993